Pfizer’s Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.
Pfizer’s Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Where Today's News Shapes Tomorrow
